AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03653104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melodica Intervention
Description: The melodica program will include education about pursed lip breathing, instruction in the melodica instrument, and participation in a melodica training group which meets twice-weekly for an 8-week period. Each session will include musical instruction, group music-making, and education about COPD and related health topics.
Study NCT03653104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Health Education
Description: A single session including education about COPD and related health topics.
Study NCT05359991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
Study NCT05359991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Cardiopulmonary Exercise Testing (CPET) will be used with Multiple Brief Exercise Bouts (MBEB) in order to obtain the necessary data to yield information on the study outcome variables
Study NCT01903642 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: proteomic analysis
Study NCT01546974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HME filter Twin Star 55, Drager Medical, Germany
Study NCT01546974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated humidification
Study NCT01641237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fluoride
Description: fluoride as sodium fluoride
Study NCT01641237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: no added fluoride in a silica base
Description: no added fluoride
Study NCT04678596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EonAligner
Description: EonAligner system is one stage system.
Study NCT04678596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clearfix
Description: Clearfix system is three-stage system.
Study NCT06228651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Study NCT06228651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The leg without the tourniquet
Study NCT04127825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Normovolemic Hemodilution (ANH)
Description: Acute normovolemic hemodilution (ANH) is a method of blood conservation used to reduce the amount of donor blood transfused. It involves removing blood from appropriate patients immediately after the induction of anesthesia, replacing the volume lost with colloids (e.g. 5% albumin), then storing and returning this blood to the patient at the completion of the surgical procedures.
Study NCT02825004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Intervention
Study NCT04549727 — intervention group
Intervention type: OTHER
Intervention: Organoids creation
Description: Organoids are created from discarded tissue
Study NCT00286481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and simvastatin
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Study NCT00286481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and simvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Study NCT00286481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
Study NCT00909181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo
Study NCT00909181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxybutynin
Description: Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo
Study NCT00909181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo
Study NCT00909181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo
Study NCT02336789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fecal material
Description: . All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
Study NCT02336789 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
Study NCT04573751 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
Study NCT04573751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
Study NCT04573751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
Study NCT04573751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine + verapamil
Description: Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
Study NCT05368961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Distraction (interactive tablet)
Study NCT05368961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Anxiolytic ordered by anesthesiologist is usual care
Study NCT05197517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10 mg
Description: Film Coated Tablets products containing 10 mg Rosuvastatin
Study NCT05197517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Description: Film Coated Tablets products containing 10 mg Rosuvastatin
Study NCT02908425 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Statin user
Description: Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
Study NCT00127868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo
Study NCT00127868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo
Study NCT00408330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic Acid 15% Gel
Description: 15% gel, topically applied daily for six weeks
Study NCT00408330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive 15% gel base
Description: placebo, topically applied daily for six weeks
Study NCT00862303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
Study NCT00862303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IL-2/IFN-α
Description: Patients receive treatment of IL-2 or IFN-α.
Study NCT02560064 — intervention group
Intervention type: PROCEDURE
Intervention: Laparotomy
Description: Small bowel length will measure in laparotomy, regardless of indication.
Study NCT03148678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Subjects are provided with smartphone-based mindfulness intervention.
Study NCT03148678 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mindfulness
Description: Subjects are provided with smartphone-based mindfulness intervention.
Study NCT03148678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contingent RT-fMRI-NF
Description: Subjects are provided with contingent RT-fMRI-NF of their own brain activity.
Study NCT03148678 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham RT-fMRI-NF
Description: Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
Study NCT03148678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Wandering
Description: Subjects are provided with smartphone-based mind wandering intervention.
Study NCT03148678 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mind Wandering
Description: Subjects are provided with smartphone-based mind wandering intervention.
Study NCT04216186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Atomoxetine once daily
Study NCT04216186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q
Description: Coenzyme Q once daily
Study NCT04216186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Coenzyme Q
Description: Coenzyme Q once daily
Study NCT01383161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Six Theracurmin capsules (containing 30 mg of curcumin each) per day for 18 months.
Study NCT01383161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six capsules per day for 18 months.
Study NCT03099239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hCT-MSC infusion
Description: hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
Study NCT03706404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-Care ultrasound and testing
Description: Point-of-Care ultrasound + Point-of-Care blood gas testing
Study NCT02675023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M923
Description: Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
Study NCT04440787 — intervention group
Intervention type: PROCEDURE
Intervention: Three point cuff palpation technique
Description: the ETT is finally positioned according to the Three point cuff technique.
Study NCT03575078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ761, Olaparib
Description: ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
Study NCT00068588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV
Study NCT00068588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT03415126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN007: ascending doses
Description: Oral drug for the treatment of advanced solid tumors
Study NCT03415126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN007 RD
Description: Oral drug for the treatment of advanced solid tumors
Study NCT01899625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Behavioral Weight Loss (BWL)
Description: 12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
Study NCT01899625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivation Enhanced BWL
Description: 12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
Study NCT01447368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
Study NCT01447368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical total parathyroidectomy with forearm autografting
Description: Surgical total parathyroidectomy with forearm autografting will be performed
Study NCT03155373 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac catheterisation
Description: Pre-operative left heart catheterisation +/- right heart catheterisation
Study NCT03155373 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing
Description: Pre and post-operative cardiopulmonary exercise testing
Study NCT03155373 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function tests
Description: Pre and post-operative pulmonary function tests
Study NCT03155373 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Pre and post-operative cardiac MRI
Study NCT03155373 — intervention group
Intervention type: OTHER
Intervention: Quality of life survey
Description: Pre and post-operative quality of life survey (SF36)
Study NCT03155373 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve operation
Description: Clinically indicated mitral valve repair/replacement +/- coronary artery surgery +/- tricuspid valve surgery +/- atrial fibrillation surgery
Study NCT03155373 — intervention group
Intervention type: PROCEDURE
Intervention: Myocardial biopsies
Description: Right and left epicardial ventricular biopsies taken at time of clinically indicated surgery
Study NCT02199600 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GMK Sphere Knee Replacement
Study NCT04575025 — intervention group
Intervention type: DRUG
Intervention: Tabrecta tablets
Description: There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT02042430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO
Study NCT02042430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02042430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT03738969 — intervention group
Intervention type: PROCEDURE
Intervention: Laparotomic radical hysterectomy
Description: Radical hysterectomy applied by laparotomy
Study NCT03738969 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic radical hysterectomy
Description: Radical hysterectomy applied by laparoscopic
Study NCT00564785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synera(TM)
Description: Synera(TM) patch applied 20 minutes prior to epidural
Study NCT00564785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch applied 20 minutes prior to epidural
Study NCT02150499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol tartrate HFA inhalation aerosol
Study NCT02150499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT03371758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.
Study NCT02887872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation-dynamic hand orthosis
Description: Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
Study NCT04505904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon
Description: Synthetic oxytocin spray, 24 IU per spray.
Study NCT04505904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: Synthetic oxytocin spray, 24 IU per spray.
Study NCT04505904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo spray with no active ingredient.
Study NCT04505904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo spray with no active ingredient.
Study NCT04052529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary self-monitoring
Description: Participants use a popular smartphone application to track their food and drink intake for one month.
Study NCT00767364 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
Description: Oral vaccine for prevention of rotavirus infection, 3 dose series
Study NCT00767364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
Description: Oral vaccine for prevention of rotavirus infection, 3 dose series
Study NCT03892512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol Hydrochloride
Description: Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )
Study NCT03892512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )
Study NCT01063829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg AIC246
Description: Oral administration
Study NCT01063829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg AIC246
Description: Oral administration
Study NCT01063829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 240 mg AIC246
Description: Oral administration
Study NCT01063829 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Oral administration
Study NCT02783131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedNav
Description: MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
Study NCT03447366 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mitral doppler
Description: Mitral doppler before and after vascular filling
Study NCT01122576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crystalens AO
Description: Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
Study NCT01122576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReSTOR
Description: ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
Study NCT01122576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis Multifocal IOL
Description: Tecnis surgically implanted bilaterally. Study observation up to 180 days.
Study NCT03274583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Smartphone seismographic recording
Description: A short recording of heart rhythm using a smartphone.
Study NCT01829360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment (interactive book reading, dialogic reading, shared book reading)
Description: Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.